<div>
<p>In recent trading, shares of Atara Biotherapeutics Inc (Symbol: ATRA) have crossed above the average analyst 12-month target price of $9.33, changing hands for $9.93/share.  When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.  Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.</p><p>
There are 3 different analyst targets within the Zacks coverage universe contributing to that average for Atara Biotherapeutics Inc, but the average is just that — a mathematical average.  There are analysts with lower targets than the average, including one looking for a price of $4.00.  And then on the other side of the spectrum one analyst has a target as high as $18.00.  The standard deviation is $7.571.

</p><p>
But the whole reason to look at the <i>average</i> ATRA price target in the first place is to tap into a &#34;wisdom of crowds&#34; effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes.  And so with ATRA crossing above that average target price of $9.33/share, investors in ATRA have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $9.33 just one stop on the way to an even <i>higher</i> target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?  Below is a table showing the current thinking of the analysts that cover Atara Biotherapeutics Inc:

</p><p>
</p><section><table>
<tbody><tr>
<th colspan="5"><b>Recent ATRA Analyst Ratings Breakdown</b></th>
</tr>
<tr>
<td>»</td>
<td align="right">Current</td>
<td align="right">1 Month Ago</td>
<td align="right">2 Month Ago</td>
<td align="right">3 Month Ago</td>
</tr>
<tr>
<td>Strong buy ratings:</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td>Buy ratings:</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Hold ratings:</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">5</td>
</tr>
<tr>
<td>Sell ratings:</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Strong sell ratings:</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td><i>Average rating:</i></td>
<td align="right"><i>2.67</i></td>
<td align="right"><i>2.71</i></td>
<td align="right"><i>2.75</i></td>
<td align="right"><i>2.75</i></td>
</tr></tbody></table></section><p>
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell.  This article used data provided by Zacks Investment Research via Quandl.com.  Get the latest Zacks research report on ATRA — FREE.
	</p><p>
<img height="16" src="https://imageproxy.pbkrs.com/https://www.dividendchannel.com/nslideshow.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" original-src="https://imageproxy.pbkrs.com/https://www.dividendchannel.com/nslideshow.gif"/> 10 ETFs With Most Upside To Analyst Targets »
</p><p>
</p><h5>Also see:</h5><p>
	 Chemicals Dividend Stocks<br/>
	 EW Stock Split History<br/>
	 High Yield REITs<br/>
</p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

ATRA

SBIO

LABD

LABU

<p>Atara Biotherapeutics Inc (ATRA) shares have surpassed the average analyst 12-month target price of $9.33, trading at $9.93. Analysts may react by downgrading or raising their target prices based on company developments. Current analyst targets range from $4.00 to $18.00, with a standard deviation of $7.571. Investors are encouraged to evaluate whether the stock's rise indicates further potential or if it's time to sell. Recent ratings show a mix of strong buy, hold, and sell recommendations, with an average rating of 2.67 on a scale where 1 is Strong Buy and 5 is Strong Sell.</p>

ATRA Crosses Above Average Analyst Target